Latest News and Press Releases

SAN DIEGO, CA--(Marketwire - Aug 9, 2012) - Cytori Therapeutics (NASDAQ: CYTX) has expanded the Celution® System CE Mark in Europe to include several new indications, including cryptoglandular...

SAN DIEGO, CA--(Marketwire - Aug 8, 2012) - During the second quarter and first half of 2012, Cytori Therapeutics (NASDAQ: CYTX) made key advancements in its cardiac cell therapy pipeline, achieved...

SAN DIEGO, CA--(Marketwire - Jul 26, 2012) - Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Wednesday, August 8, 2012...

SAN DIEGO, CA--(Marketwire - May 30, 2012) - Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical uses. These clinical uses...

SAN DIEGO, CA--(Marketwire - May 23, 2012) - Cytori Therapeutics (NASDAQ: CYTX) will present and provide a corporate update from the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5,...

SAN DIEGO, CA--(Marketwire - May 9, 2012) - During the first quarter of 2012, Cytori Therapeutics (NASDAQ: CYTX) advanced its cardiac cell therapy product pipeline, grew the commercial business,...

SAN DIEGO, CA--(Marketwire - Apr 27, 2012) - Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Wednesday, May 9, 2012 at...

ZUG, SWITZERLAND and SAN DIEGO, CA--(Marketwire - Mar 19, 2012) - Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal...

SAN DIEGO, CA--(Marketwire - Mar 16, 2012) - Cytori (NASDAQ: CYTX) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Puregraft® 850 System for body...

SAN DIEGO, CA--(Marketwire - Mar 8, 2012) - In 2011, Cytori Therapeutics (NASDAQ: CYTX) achieved important objectives towards validating Celution® technology in multiple large market...